Emergency Medicine Cardiac Research and Education Group




ACTION Registry
ACTION Registry®–GWTG™ is a national, risk-adjusted, outcomes-based quality improvement program that helps participating facilities measure and improve care for high-risk ACS patients with STEMI and NSTEMI. The result of the collaboration between the two leading national coronary artery disease registries, the NCDR® ACTION Registry® and the American Heart Association (AHA) Get With The GuidelinesSM-CAD Registry, ACTION Registry–GWTG will be the largest, most comprehensive national cardiovascular patient database ever developed by the medical profession.

Combining the strengths of the two programs, ACTION Registry–GWTG will collect a comprehensive set of data elements that provide healthcare professionals and their facilities with the information they need to monitor and improve adherence to the most current, science-based ACC/AHA treatment guidelines. Participation will greatly facilitate quality improvement efforts, optimize clinical care, and improve clinical outcomes for acute coronary syndrome patients.

Visit How To Join to request additional information or to download an enrollment package. Or, visit the ACTION website for more information.






With well over one and a half million combined Emergency Department (ED) visits at EMCREG sites annually, EMCREG-International is ideally positioned to conduct clinical trials quickly and efficiently. Additionally, as academic emergency clinician educators, EMCREG provides an ideal format for educating the emergency medicine community on cutting-edge evidence-based research, and facilitate acceptance and understanding of current treatment guidelines.

The wealth of experience and clinical acumen associated with such a geographically diverse network of veteran clinician researchers has resulted in the development of the consultation arm of EMCREG-International. These consultation efforts are geared toward helping companies understand both the clinical usefulness and obstacles associated with embracing a new diagnostic or treatment technology in the clinical ED setting. The drive to identify and assess new technologies is equally important to the clinicians making up the EMCREG network as it is to the manufacturers of diagnostic and therapeutic modalities.

The ability to consult with such a large number of well known and geographically diverse emergency physicians in a round table discussion setting has proved invaluable to industry efforts to assess the clinical utility of a promising new diagnostic or therapeutic technology. Will a promising technology ultimately be practical in the clinical ED setting in its current form?; What are the practical, clinical and political obstacles to adopting promising new technologies?; and What alterations to a technology or its marketing would allow its utility and acceptance in the ED to be realized? This ability to rapidly organize such an expert panel with minimal effort has proved appealing for companies facing short development timelines.

Please feel free to contact our offices if the idea of a consultation roundtable or collaboration interests your organization.






Legal information

EMCREG™ - International
4555 Lake Forest Drive
Suite 650
Cincinnati, Ohio 45242

Fell free to contact us toll-free at 1-866-4EMCREG (436-2734)



Advanced Search

5 March 2010
Computed tomography angiography provides important additional prognostic information, but it's role in clinical practice is still not known.
11 February 2010
Researchers report that a novel method for using natriuretic-peptide testing can optimize postdischarge therapy after acute heart-failure decompensation, reduce hospitalization, and improve outcomes.
28 January 2010
Study results show that the TIMI risk score predicts outcomes in emergency department with suspected ACS.
28 January 2010
Serial measurement of NT-proBNP predicts new-onset heart failure and cardiovascular mortality in elderly.
15 January 2010
Results of the PLATO trial show that the reversible P2Y12 inhibitor ticagrelor reduces death and cardiovascular events compared with clopidogrel therapy in ACS patients.
15 January 2010
Individual risk profiling of ACS patients could optimize therapeutic treatment choices.
5 January 2010
Study shows that high sensitive cardiac troponin I level is a useful prognostic marker of mortality in chronic heart failure patients.
23 December 2009
The largest and most comprehensive meta-analysis ever concludes that CRP is unlikely to be a causal factor for cardiovascular disease.
16 December 2009
Research shows that a substantial number of STEMI patients still receive fibrinolytic therapy at PCI capable centers.
11 December 2009
Denmark researchers report in Lancet that relative risk for hospitalization for bleeding increased with all drug combinations and with each additional drug used.
3 December 2009
Researchers report that prehospital triage significantly reduces treatment delay and improves outcomes in STEMI patients who undergo PCI.
30 November 2009
Researchers report that the to reperfusion, beginning with symptom onset time, determines the extent of reversible myocardial injury in STEMI patients undergoing PCI.
NEWS ARCHIVES:
©Copyright EMCREG-International™. All rights reserved